The investigators intended for this study to deliver the "proof-of-concept" that locally
administered pilocarpine drops in two doses are effective in a population of elderly (aged ≥
70 years) with xerostomia at the expense of limited adverse events. To this end, the study
aims to quantify the effect size of pilocarpine in two different dosages. In case the
investigators observe clinically meaningful changes in xerostomia through measured NRS, a
sufficiently-powered RCT will be prepared to compare pilocarpine to placebo.